New drug duo targets hard-to-treat blood cancers
NCT ID NCT07615283
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests two drugs, adebrelimab and SHR2554, together in about 40 adults whose T-cell lymphoma has come back or not responded to treatment. The goal is to find a safe dose and see if the combination can shrink tumors. Participants must have certain types of T-cell lymphoma and meet other health criteria.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NKTCL are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sun Yat-sen University Cancer Center
Guangzhou, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a drug duo outsmart resistant T-Cell lymphoma?
- Experimental drug chidamide targets Hard-to-Treat blood cancer
- Promising cocktail of drugs targets rare blood cancer
- New combo attack on rare blood cancer shows promise in early trial
- Experimental lymphoma drug ASTX660 tested in tiny, terminated trial
- New pill shows promise for Hard-to-Treat cancers